Ceftolozane/Tazobactam as a Treatment for Multidrug-Resistant P. aeruginosa in a Ventricle-Peritoneal Shunt

VP shunt infections are among the most severe complications following neurosurgical interventions, with infection rates ranging from 5–15%. The growing prevalence of MDR Gram-negative bacteria, especially P. aeruginosa, has complicated management. Treatment failures with carbapenems and aminoglycosides due to rising resistance necessitate alternatives. Ceftolozane/tazobactam, a novel oxyimino-cephalosporin/beta-lactamase inhibitor, demonstrates unique anti-pseudomonal activity and broad Gram-negative coverage, making it a candidate for salvage therapy in severe VP shunt infections

·        VP shunt infections often follow operative contamination or hematogenous spread.

·        Recent data reveal a significant shift toward Gram-negative pathogens in neurosurgical devices^[1].

·        P. aeruginosa thrives in the CSF and biofilm matrix, exhibiting resistance via efflux pumps, enzyme production (AmpC, ESBLs), porin modification, and, increasingly, carbapenemases.

·        Biofilm formation on shunts protects bacteria from host responses and antibiotics, necessitating drugs with both planktonic and biofilm activity.

Rationale and Mechanism for Ceftolozane/Tazobactam

·        Ceftolozane: A cephalosporin with enhanced stability against AmpC and increased affinity for P. aeruginosa penicillin-binding proteins.

·        Tazobactam: A beta-lactamase inhibitor protecting ceftolozane from hydrolysis.

·        Demonstrated superior in vitro activity against MDR and carbapenem-non-susceptible P. aeruginosa strains^[2][3][1].

Clinical Efficacy in CNS/VP Shunt Infections

·        Case reports and small series support clinical use; for instance, a pediatric VP shunt infection by MDR P. aeruginosa cleared after 28 days of ceftolozane/tazobactam therapy, combined with shunt externalization. CSF cultures remained negative with no relapse^[4][5].

·        Broader retrospective studies of MDR-P. aeruginosa infections (mostly non-CNS) show clinical cure rates of 70–71%, though emergence of resistance during treatment was observed in up to 14% of cases^[2][3].

·        A recent microbiology surveillance highlights growing resistance to carbapenems and beta-lactam/beta-lactamase inhibitor combinations, suggesting ceftolozane/tazobactam as a necessary addition to the therapeutic arsenal for VP shunt infections^[1].

Table 1. Clinical Success of Ceftolozane/Tazobactam in MDR P. aeruginosa Infections

Pharmacokinetics and CNS Penetration

·        CSF penetration of ceftolozane/tazobactam is modest (~20%), likely insufficient as monotherapy for meningitis unless the MIC is very low (<0.25mg/L), suggesting utility is highest when combined with device removal/externalization and in susceptible isolates^[6].

·        Higher doses or prolonged infusions may optimize CSF exposure; further research is needed on intracerebroventricular administration in select cases.

Graph: Comparative CSF and Plasma Concentrations of Ceftolozane/Tazobactam

[image:1]

Challenges: Resistance, Device Management, and Stewardship

·        Drug resistance may arise rapidly, often via ampC overexpression or mutation; clinical failure is rarely due to acquisition of new resistance genes during treatment but due to selection of resistant subpopulations^[2].

·        Shunt externalization or removal, with conversion to an external ventricular drain, is critical for infection clearance, as antibiotics alone are rarely curative in the setting of biofilm.

·        Intrathecal administration remains controversial but may be considered in refractory cases^[1].

Practical Considerations and Future Directions

·        Early and aggressive stewardship interventions, prompt organism identification, and MIC-guided therapy selection are paramount.

·        Consider maximum recommended dosing for CNS penetration, with therapeutic drug monitoring where available.

·        Multidisciplinary care—neurosurgery, infectious disease, pharmacy—is essential for optimal outcomes.

Table 2. Recommended Drug Options and Strategies for MDR Gram-Negative VP Shunt Infections

Ceftolozane/tazobactam represents a promising option in the salvage therapy of MDR P. aeruginosa infections in VP shunt settings. Successful outcomes rely on an integrated approach incorporating antibiotic therapy (at high dose), device management, and multidisciplinary care. Ongoing surveillance and resistance monitoring remain key for stewardship. Further prospective studies are warranted to validate optimal dosing strategies and clarify the role of intraventricular administration.

Figure 1: CSF and Plasma Concentrations of Ceftolozane/Tazobactam

Illustrates the trough and peak levels achieved with standard and high-dose regimens in CSF compared to plasma, emphasizing the pharmacokinetic challenges in CNS infection^[6].

[image:1]

1.      Kumar, S., et al. “Bacterial ventriculoperitoneal shunt infections: changing trends in organisms & antimicrobial susceptibilities.” Microorganisms, 2023.

2.      Li, Caitlin, et al. "Hardware-Associated Multidrug-resistant Pseudomonas aeruginosa Meningitis Treated with Ceftolozane-Tazobactam." Open Forum Infectious Diseases, 2020.

3.      Ghady, Haidar, et al. "Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance." Clinical Infectious Diseases, 2017.